Does Aetna Cover Farxiga?

Aetna Formulary Placement for Farxiga

Farxiga (dapagliflozin) appears on Aetna's national preferred formulary as a Tier 3 preferred brand medication. This means Aetna recognizes the drug's clinical value but applies cost-sharing that sits between generic medications (Tier 1 or 2) and non-preferred brands (Tier 4). Placement can shift slightly depending on whether you hold a commercial PPO, HMO, or Medicare Advantage plan.

Aetna updates its formularies quarterly, and SGLT2 inhibitors as a class have maintained strong positioning since the FDA expanded Farxiga's label in 2020 and 2021 to include heart failure and chronic kidney disease [1][2]. Your specific plan's formulary may differ from the national list. Aetna's online formulary lookup tool lets you verify your plan's current tier by entering your member ID and searching for "dapagliflozin" or "Farxiga." Employer-sponsored plans sometimes negotiate custom formularies that place Farxiga on a different tier or exclude it entirely in favor of empagliflozin (Jardiance), so checking your specific plan document is a necessary first step.

The 2024 American Diabetes Association Standards of Care recommend SGLT2 inhibitors as second-line therapy after metformin for patients with type 2 diabetes who have established cardiovascular disease, heart failure, or chronic kidney disease, stating that "SGLT2 inhibitors with proven cardiovascular benefit are recommended to reduce MACE, heart failure hospitalization, and CKD progression" [3]. This guideline backing strengthens the case for coverage across all major insurers.

Prior Authorization Requirements

Most Aetna plans require prior authorization before they will cover Farxiga. This is standard across the SGLT2 inhibitor class. Your prescriber submits clinical documentation to Aetna demonstrating that you meet specific criteria.

For the type 2 diabetes indication, Aetna's clinical policy bulletins typically require documentation of a current HbA1c level, confirmation that metformin has been tried or is contraindicated, and a diagnosis of type 2 diabetes [4]. For heart failure, the prescriber must document a left ventricular ejection fraction of 40% or less (consistent with the DAPA-HF trial population) or show evidence of heart failure with preserved ejection fraction based on the DELIVER trial results [5]. For chronic kidney disease, documentation of an eGFR between 25 and 75 mL/min/1.73 m² with evidence of albuminuria generally meets Aetna's criteria, reflecting the DAPA-CKD enrollment parameters [6].

Prior authorization decisions usually arrive within 72 hours for standard requests. Urgent requests can be processed in 24 hours. If your pharmacy tells you the claim was rejected, ask your prescriber's office to initiate the PA process. Many denials happen simply because the PA was never submitted, not because the patient was truly ineligible.

What You Will Pay Out of Pocket

The retail price of Farxiga without insurance runs approximately $618 for a 30-day supply of 10 mg tablets. With Aetna coverage, your costs drop substantially, but the exact amount depends on your plan design.

On a typical Aetna commercial PPO with a Tier 3 copay structure, expect to pay between $25 and $90 per fill. Plans using coinsurance instead of flat copays charge 25% to 40% of the negotiated rate, which usually lands between $40 and $75 per month after Aetna's contracted discount. High-deductible health plans paired with HSAs require you to pay the full negotiated rate (often $350 to $450) until your deductible is met, after which the Tier 3 copay kicks in.

A 2023 analysis published in Diabetes Care found that average out-of-pocket costs for branded SGLT2 inhibitors among commercially insured patients ranged from $42 to $77 per month after accounting for manufacturer coupons and plan subsidies, with higher cost-sharing directly correlating to lower adherence rates [7]. Patients paying more than $50 per month were 23% less likely to remain on therapy at 12 months compared to those paying under $25.

Aetna Medicare Advantage and Part D Coverage

Farxiga coverage under Aetna Medicare plans follows a different structure than commercial insurance. Aetna Medicare Advantage plans with integrated Part D benefits typically list Farxiga on Tier 3, but the cost-sharing model includes the well-known Medicare "donut hole" coverage gap.

During the initial coverage phase, expect copays of $47 to $100+ per month depending on your specific Aetna Medicare plan. Once your total drug spending reaches $5 to 030 in 2026 (the coverage gap threshold), your responsibility drops to 25% of the drug cost thanks to manufacturer discounts and plan subsidies under the Inflation Reduction Act provisions. The IRA's $2,000 annual out-of-pocket cap for Part D, which took full effect in 2025, means your total yearly spending on all Part D medications (including Farxiga) will not exceed $2,000 [8]. This is a meaningful change.

For Aetna Medicare Advantage members specifically, the 2024 CMS data shows that Aetna's MA-PD plans covered Farxiga on 94% of their regional formularies, though tier placement and prior authorization requirements varied by region [9]. Low-income subsidy (LIS) eligible members may pay as little as $0 to $11.20 per fill.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, noted in 2023 that "the Inflation Reduction Act provisions represent the most significant reduction in diabetes medication costs for Medicare beneficiaries in the program's history, and SGLT2 inhibitors like dapagliflozin should become substantially more accessible" [10].

Step Therapy and What It Means for You

Step therapy (sometimes called "fail first") is a protocol where Aetna requires you to try a less expensive medication before approving a costlier one. For Farxiga prescribed for type 2 diabetes, Aetna commonly requires a documented trial of metformin lasting at least 90 days, unless metformin is contraindicated due to renal impairment (eGFR <30 mL/min/1.73 m²), gastrointestinal intolerance, or lactic acidosis risk.

Step therapy does not typically apply when Farxiga is prescribed for heart failure or chronic kidney disease. These are distinct FDA-approved indications where SGLT2 inhibitors have demonstrated benefit independent of diabetes status [5]. In the DAPA-HF trial (N=4,744), dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001), with benefits observed regardless of whether patients had diabetes [5]. If your prescriber documents the heart failure or CKD indication clearly on the prior authorization form, step therapy requirements for diabetes medications should not apply.

If your prescriber believes step therapy is clinically inappropriate for your diabetes care, they can request a step therapy exception. Valid reasons include a history of adverse reactions to metformin, clinical urgency (such as an HbA1c above 9% with cardiovascular risk factors), or evidence that the requested medication addresses a comorbid condition that metformin does not target. The ADA Standards of Care support initiating SGLT2 inhibitors as first-line therapy alongside metformin in patients with established atherosclerotic cardiovascular disease, heart failure, or CKD [3].

How to Appeal a Farxiga Coverage Denial

If Aetna denies coverage for Farxiga, you have the right to appeal. The process involves two internal levels and one external review option.

A Level 1 internal appeal must be filed within 180 days of the denial. Your prescriber should submit a letter of medical necessity that references the specific clinical evidence supporting Farxiga for your condition. For diabetes, cite HbA1c values and cardiovascular or renal comorbidities. For heart failure, include echocardiography results showing ejection fraction. For CKD, provide recent eGFR and urine albumin-to-creatinine ratio (UACR) values. Referencing the relevant clinical trial data strengthens the appeal. The DECLARE-TIMI 58 trial (N=17,160) demonstrated that dapagliflozin reduced hospitalization for heart failure by 27% (HR 0.73 to 95% CI 0.61 to 0.88) in patients with type 2 diabetes and cardiovascular risk factors [11].

If the Level 1 appeal fails, a Level 2 appeal goes to a different set of Aetna reviewers. If both internal appeals are denied, you can request an independent external review through your state's insurance department. External reviewers are not employed by Aetna and evaluate the clinical evidence independently.

Dr. Mikhail Kosiborod, a cardiologist at Saint Luke's Mid America Heart Institute, has stated that "the cardiovascular and renal evidence for SGLT2 inhibitors is now so strong that denial of coverage is increasingly difficult to justify on clinical grounds, particularly for patients with heart failure or CKD" [12]. Including such expert perspectives in appeal letters can reinforce the clinical rationale.

AstraZeneca Savings Programs and Copay Cards

AstraZeneca offers several assistance programs that can dramatically reduce your Farxiga costs even with Aetna coverage.

The Farxiga Savings Card is available to commercially insured patients (including those with Aetna commercial plans) and can reduce copays to as little as $0 per month, with a maximum annual benefit of $3,400 [13]. The card cannot be used with government insurance, including Medicare, Medicaid, or Tricare. Enrollment is straightforward and can be completed online or through your prescriber's office.

For patients without insurance or who face financial hardship, AstraZeneca's AZ&Me patient assistance program provides Farxiga at no cost to qualifying individuals. Eligibility is based on income (generally at or below 400% of the federal poverty level) and lack of prescription drug coverage. The application requires documentation of income and a prescription from your provider.

Aetna members should also check whether their plan offers a specialty pharmacy benefit with lower cost-sharing for certain medications. Some Aetna plans route SGLT2 inhibitors through CVS Specialty (Aetna's parent company is CVS Health), which may offer different pricing than retail pharmacies. Comparing costs between your local pharmacy and Aetna's preferred mail-order service can reveal savings of 10% to 20% on 90-day supplies.

Farxiga vs. Jardiance on Aetna Formularies

Both Farxiga (dapagliflozin) and Jardiance (empagliflozin) are SGLT2 inhibitors, and Aetna covers both on most formularies. The relative tier placement between the two drugs varies by plan year and negotiated rebates.

In recent formulary cycles, Aetna has generally placed both medications on the same tier (Tier 3 preferred brand), though some employer-sponsored plans may prefer one over the other based on pharmacy benefit manager negotiations. If Aetna denies Farxiga but covers Jardiance at a lower tier, switching to Jardiance is a reasonable clinical option. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% (HR 0.62 to 95% CI 0.49 to 0.77, P<0.001) in patients with type 2 diabetes and established cardiovascular disease [14]. Head-to-head data between the two drugs is limited, and both carry similar class-effect benefits for cardiorenal protection.

The choice between them often comes down to which drug your insurer offers at a lower copay. Ask your prescriber whether either drug is clinically preferable for your specific situation. For patients prescribed Farxiga specifically for CKD, the evidence base is particularly strong. The DAPA-CKD trial showed dapagliflozin reduced the composite endpoint of sustained decline in eGFR of 50% or more, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) compared with placebo [6]. This trial led to the FDA granting Farxiga a CKD indication regardless of diabetes status, making it the first SGLT2 inhibitor approved for this use.

Getting Your Prescription Covered Efficiently

Start by calling the number on the back of your Aetna card and asking the pharmacy benefits team to confirm Farxiga's formulary status, tier, and prior authorization requirements for your specific plan. Write down the reference number for that call.

Next, ensure your prescriber's office has your updated Aetna information and understands the PA requirements. Many large health systems have dedicated prior authorization staff who handle these submissions routinely. If your provider uses an electronic prior authorization (ePA) system like CoverMyMeds, the process may be completed within hours rather than days. A 2022 AMA survey found that physicians spend an average of 13 hours per week on prior authorization activities, and ePA systems cut approval times by roughly 60% [15].

Have your prescriber document the specific FDA-approved indication (type 2 diabetes, heart failure, or CKD) and the clinical rationale on the PA form. If step therapy applies, ensure prior metformin use (or contraindication) is clearly noted. Enroll in the AstraZeneca savings card before filling your first prescription so the copay reduction applies immediately.

If you receive a denial, do not abandon the medication. Request the denial reason in writing, have your prescriber file the appeal with supporting clinical documentation, and contact Aetna's member services to confirm the appeal is being processed. The entire process from initial PA submission to final appeal resolution typically takes 2 to 6 weeks.